M
IMEPro
J84.10 Respiratory
Updated March 2026

Pulmonary fibrosis, unspecified

ICD-10 Code: J84.10 · Body Part: Head/Brain (TBI)

QME Evaluation Process

PFTs (restrictive pattern, decreased DLCO), high-resolution CT, exposure history. Chapter 5 respiratory impairment. Differentiate occupational vs idiopathic fibrosis.

Typical Impairment Rating

20-65% WPI depending on PFT severity

AMA Guides Edition

5th Edition

Common Treatments

+ Antifibrotic medication
+ Supplemental oxygen
+ Pulmonary rehabilitation
+ Lung transplant evaluation

Related Conditions

Body Part Guide

Head/Brain (TBI) Evaluation Guide

Impairment rating methods, common conditions, and QME evaluation protocols

View Guide →

QME Specialties for Pulmonary fibrosis, unspecified

Find a QME Specialist

Browse QME-certified physicians who evaluate pulmonary fibrosis, unspecified and related head/brain (tbi) conditions in California.

Browse Neurology Physicians →

Frequently Asked Questions

What is Pulmonary fibrosis, unspecified (J84.10)?

Pulmonary fibrosis, unspecified is an ICD-10 diagnosis code (J84.10) classified under Respiratory conditions. It affects the Head/Brain (TBI) and is commonly encountered in California workers' compensation claims. QME physicians evaluate this condition using AMA Guides 5th Edition protocols.

How is J84.10 rated for impairment?

The typical whole person impairment (WPI) range for Pulmonary fibrosis, unspecified is 20-65% WPI depending on PFT severity. The exact rating depends on clinical findings, imaging, and the evaluation method (DRE or ROM) chosen by the QME physician per AMA Guides 5th Edition.

What is the QME evaluation process for J84.10?

PFTs (restrictive pattern, decreased DLCO), high-resolution CT, exposure history. Chapter 5 respiratory impairment. Differentiate occupational vs idiopathic fibrosis.

What treatments are common for Pulmonary fibrosis, unspecified?

Common treatments for Pulmonary fibrosis, unspecified include Antifibrotic medication, Supplemental oxygen, Pulmonary rehabilitation, Lung transplant evaluation. Treatment appropriateness and outcomes are considered during the QME evaluation when determining permanent and stationary status and apportionment.